AI Summary
Thinking
Thinking
We reviewed 3 live results for upadacitinib and narrowed them down to the 3 options that look most worth comparing first.
The options are Rinvoq (Upadacitinib), Upadacitinib and RINVOQ (upadacitinib) Tablets.
Source: PharmaServe
Description
Rinvoq (Upadacitinib) is a prescription pharmaceutical tablet formulation designed for oral administration. Offered on PharmaServe, it is available across multiple dosage strengths and packaging configurations, including 15mg (30 and 60 count), 30mg (30 count), and 45mg (28 count) options. The medication requires prescription submission and adheres to regulations restricting orders to a maximum supply of three months.
Best for
Patients with a valid prescription for Upadacitinib and Filling or refilling prescription Upadacitinib oral medication
Rate this product
Source: 24/7QualityMeds
Description
Upadacitinib, marketed under the brand name Rinvoq and Rinvoq LQ, is a prescription Janus kinase (JAK) inhibitor formulated as extended-release tablets (15 mg, 30 mg, and 45 mg) and an oral solution (1 mg/mL). It is indicated for treating active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, nonradiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, especially in patients with inadequate response or intolerance to TNF blockers.
Best for
Patients with moderate to severe autoimmune or chronic inflammatory diseases, Patients with inadequate response or intolerance to TNF blockers, Treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and Treatment of refractory moderate to severe atopic dermatitis
Rate this product
Source: Alleviare Life Sciences Pvt. Ltd.
Description
RINVOQ (upadacitinib) is an oral prescription Janus kinase (JAK) inhibitor extended-release tablet marketed by AbbVie. Available in 15 mg, 30 mg, and 45 mg strengths, it is indicated for treating conditions including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, and ankylosing spondylitis in eligible patients who have had inadequate responses or intolerance to TNF blockers. Facilitated in India through Named Patient Programs, access requires a valid doctor prescription and relevant documentation.
Best for
Adults with moderate to severe rheumatoid arthritis, Adults with ulcerative colitis or Crohn's disease and Patients who did not respond well or were intolerant to TNF blockers
Rate this product
| Compare | #1Rinvoq (Upadacitinib) | #2Upadacitinib | #3RINVOQ (upadacitinib) Tablets |
|---|---|---|---|
| Source | PharmaServe | 24/7QualityMeds | Alleviare Life Sciences Pvt. Ltd. |
| Description | Rinvoq (Upadacitinib) is a prescription pharmaceutical tablet formulation designed for oral administration. Offered on PharmaServe, it is available across multiple dosage strengths and packaging configurations, including 15mg (30 and 60 count), 30mg (30 count), and 45mg (28 count) options. The medication requires prescription submission and adheres to regulations restricting orders to a maximum supply of three months. | Upadacitinib, marketed under the brand name Rinvoq and Rinvoq LQ, is a prescription Janus kinase (JAK) inhibitor formulated as extended-release tablets (15 mg, 30 mg, and 45 mg) and an oral solution (1 mg/mL). It is indicated for treating active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, nonradiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, especially in patients with inadequate response or intolerance to TNF blockers. | RINVOQ (upadacitinib) is an oral prescription Janus kinase (JAK) inhibitor extended-release tablet marketed by AbbVie. Available in 15 mg, 30 mg, and 45 mg strengths, it is indicated for treating conditions including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, and ankylosing spondylitis in eligible patients who have had inadequate responses or intolerance to TNF blockers. Facilitated in India through Named Patient Programs, access requires a valid doctor prescription and relevant documentation. |
| Best for | Patients with a valid prescription for Upadacitinib and Filling or refilling prescription Upadacitinib oral medication | Patients with moderate to severe autoimmune or chronic inflammatory diseases, Patients with inadequate response or intolerance to TNF blockers, Treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and Treatment of refractory moderate to severe atopic dermatitis | Adults with moderate to severe rheumatoid arthritis, Adults with ulcerative colitis or Crohn's disease and Patients who did not respond well or were intolerant to TNF blockers |
| Action | PharmaServe | 24/7QualityMeds | Alleviare Life Sciences Pvt. Ltd. |
| Rate this product |
"Rinvoq (Upadacitinib) from PharmaServe."
Note: TopFind AI compiles product and service information for general comparison purposes only.